Income Tax Expense (Benefit) of Citius Pharmaceuticals, Inc. from 31 Dec 2010 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Citius Pharmaceuticals, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2010 to 30 Jun 2025.
  • Citius Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Jun 2025 was $264,240.
  • Citius Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $576,000.
  • Citius Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $576,000.
  • Citius Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $576,000.
Source SEC data
View on sec.gov
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Citius Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $264,240* +$120,240 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q3
Q1 2025 $264,240* +$120,240 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q2
Q4 2024 $264,240* +$120,240 01 Oct 2024 31 Dec 2024 10-Q 14 Feb 2025 2025 Q1
Q2 2024 $144,000 $0 0% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q3
Q1 2024 $144,000 $0 0% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q2
Q4 2023 $144,000 $0 0% 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025 2025 Q1
Q2 2023 $144,000 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q3
Q1 2023 $144,000 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q2
Q4 2022 $144,000 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q1
Q3 2021 $1,233 $1 01 Jul 2021 30 Sep 2021 10-K 15 Dec 2021 2021 FY
Q2 2021 $423 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q3
Q1 2021 $406 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q2
Q4 2020 $405 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022 2022 Q1
Q2 2014 $0 $0 $0 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2014 2014 Q3
Q1 2014 $0 $0 $0 01 Jan 2014 31 Mar 2014 10-Q 15 May 2014 2014 Q2
Q4 2013 $0 $0 $0 01 Oct 2013 31 Dec 2013 10-Q 19 Feb 2014 2014 Q1
Q3 2013 $0 $0 $0 01 Jul 2013 30 Sep 2013 10-K 06 Feb 2014 2013 FY
Q2 2013 $0 $0 $0 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014 2014 Q3
Q1 2013 $0 $0 $0 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014 2014 Q2
Q4 2012 $0 $0 $0 01 Oct 2012 31 Dec 2012 10-Q 19 Feb 2014 2014 Q1
Q3 2012 $0 $0 $0 01 Jul 2012 30 Sep 2012 10-K 06 Feb 2014 2013 FY
Q2 2012 $0 $0 $0 01 Apr 2012 30 Jun 2012 10-Q 18 Sep 2013 2013 Q3
Q1 2012 $0 $0 $0 01 Jan 2012 31 Mar 2012 10-Q 13 May 2013 2013 Q2
Q4 2011 $0 $0 $0 01 Oct 2011 31 Dec 2011 10-Q 08 Feb 2013 2013 Q1
Q3 2011 $0 $0 01 Jul 2011 30 Sep 2011 10-K 15 Jan 2013 2012 FY
Q2 2011 $0 01 Apr 2011 30 Jun 2011 10-Q 17 Aug 2012 2012 Q3
Q1 2011 $0 01 Jan 2011 31 Mar 2011 10-Q 11 May 2012 2012 Q2
Q4 2010 $0 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012 2012 Q1

Citius Pharmaceuticals, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $576,000* $0 01 Oct 2023 30 Sep 2024 10-K 27 Dec 2024 2024 FY
2023 $576,000* $0 01 Oct 2022 30 Sep 2023 10-K 27 Dec 2024 2024 FY
2022 $576,000* +$574,767 01 Oct 2021 30 Sep 2022 10-K 29 Dec 2023 2023 FY
2021 $1,233 +$492 +66% 01 Oct 2020 30 Sep 2021 10-K 15 Dec 2021 2021 FY
2020 $741 01 Oct 2019 30 Sep 2020 10-K 15 Dec 2021 2021 FY
2013 $0 $0 01 Oct 2012 30 Sep 2013 10-K 06 Feb 2014 2013 FY
2012 $0 $0 01 Oct 2011 30 Sep 2012 10-K 06 Feb 2014 2013 FY
2011 $0 01 Oct 2010 30 Sep 2011 10-K 15 Jan 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.